TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Praluent not worth the price, finds studySanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent Share XPraluent not worth the price, finds studyhttps://pharmaphorum.com/news/praluent-not-worth-the-price-finds-study/